Why Life-Science Innovation is Politically Purple

On June 28, 2016, Stephen Ezell spoke at a Center Forward Congressional briefing on “Why Life-Sciences Innovation is Politically Purple,” explaining that U.S. leadership in global life-sciences innovation has resulted from a strong bi-partisan commitment to support robust levels of public investment in basic life-sciences research while creating an environment in which continued private-sector investment in drug discovery can flourish thanks to strong intellectual property protections and a drug pricing reimbursement system that permits reasonable profits to be reinvested in future generations of biomedical innovation.